Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity
Gijs H Goossens 1 2 , Dror Dicker 3 4 , Nathalie J Farpour-Lambert 3 5 , Gema Frühbeck 3 6 , Dana Mullerova 3 7 , Euan Woodward 3 8 , Jens-Christian Holm 3 9
Accumulating evidence suggests that obesity is a major risk factor for the initiation, progression, and outcomes of coronavirus disease 2019 (COVID-19).
The European Association for the Study of Obesity (EASO), as a scientific and medical society dedicated to the promotion of health and well-being, is greatly concerned about the concomitant obesity and COVID-19 pandemics and their impact on health and society at large.
In this perspective, we will address the inherent immunological perturbations and alterations in the renin-angiotensin-aldosterone system in patients with obesity and COVID-19, and discuss how these impairments may underlie the increased susceptibility and more detrimental outcomes of COVID-19 in people with obesity.
Clearly, this has important implications for preventive measures, vaccination, and future therapeutic strategies to combat COVID-19.
Furthermore, we will highlight important knowledge gaps and provide suggestions for future research and recommendations for policy actions. Since many new reports on COVID-19 rapidly appear, the present perspective should be seen as a focus for discussion to drive forward further understanding, research initiatives, and clinical management of COVID-19.
CITA DEL ARTÍCULO Obes Facts. 2020 Aug 13;1-14. doi: 10.1159/000510719